Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
 Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, UT

Trial Information

Schizophrenia

A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group study to evaluate prevention of relapse in patients with schizophrenia receiving either flexible dose iloperidone or placebo in long term use (up to 26 weeks) followed by up to 52 weeks of open-label extension.

Patient Inclusion Criteria:

  • Males or Females ages 18-65
  • BMI >7 and <40 kg/mg2
  • Clear diagnosis of schizophrenia

Patient Exclusion Criteria:

  • Patients who have been hospitalized for suicidal ideation
  • Patients having clinically significant neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal and or urological disorders

Cher Struck, Director Marketing and Recruiting
Lifetree Clinical Research
3838 South 700 East Suite 202
Salt Lake CIty, UT 84106
Phone: 801-269-8200
Email: chers@lifetreeresearch.com

View Map

Research Center Information: Lifetree Clinical Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.